Apalutamide radio-sensitisation of prostate cancer.

Christos KakouratosDimitra KalamidaIoannis LamprouErasmia XanthopoulouChristos NanosAlexandra GiatromanolakiMichael I Koukourakis

Published in: British journal of cancer (2021)

In vitro and in vivo experiments support the superiority of apalutamide over bicalutamide in combination with radiotherapy in prostate cancer. Clinical studies are encouraged to show whether replacement of bicalutamide with apalutamide may improve the curability rates.

Keyphrases

prostate cancer
radical prostatectomy
early stage
radiation therapy
locally advanced
squamous cell carcinoma
rectal cancer